Acquired haemophilia A: Balancing on the edge of haemostasis – Case series
References
- Knoebl P, Marco P, Baudo P, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012; 10(4): 622–31. doi: 10.1111/j.1538-7836.2012.04654.x.
- Tiede A, Collins P, Knoebl P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica 2020; 105(7): 1791–1801. doi: 10.3324/haematol.2019.230771.
- Reich L, Gatzke F, Rauchfuss S, Roth S, Miesbach W. Prognostic factors for recurrence in acquired hemophilia A-results from a long-term observational study. Res Pract Thromb Haemost 2025; 9(2): p. 102707. doi: 10.1016/j.rpth.2025.102707.
- Tiede A, Hart C, Knobl P, et al. Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study. Lancet Haematol 2023; 10(11): e913–e921. doi: 10.1016/S2352-3026(23)00280-6.
- Tiede A, Kemkes-Matthes B, Knobl P. Should emicizumab be used in patients with acquired hemophilia A? J Thromb Haemost 2021; 19(3): 637–644. doi: 10.1111/jth.15208.
- Holstein K, Xiaofei L, Smith A, et al. Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study. Blood 2020; 136(3): 279–287. doi: 10.1182/blood.2019003639.
- Schep SJ, van Dijk WEM, Beckers EAM, et al. Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study. Am J Hematol 2021; 96(1): 51–59. doi: 10.1002/ajh.26009.
- Pasca S, Zanon E, Mannucci PM, Peyvandi F. Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding. Blood Transfus 2023; 21(6): 549–556. doi: 10.2450/2023.0247-22.
- Shima M, Amano K, Ogawa Y, et al. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. J Thromb Haemost 2023; 21(3): 534–545. doi: 10.1016/j.jtha.2022.10.004.
- Howard M, McKinley D, Sanabria F, Ko RH, Nissen F. Evaluation of the safety of emicizumab prophylaxis in persons with hemophilia A: an updated summary of thrombotic events and thrombotic microangiopathies. Blood 2021; 138(Supplement 1): 3186–3186. doi: 10.1182/blood-2021-146147.
- Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377(9): 809–818. doi: 10.1056/NEJMoa1703068.
DOI: https://doi.org/10.2478/jhp-2025-0008 | Journal eISSN: 2055-3390
Language: English
Page range: 82 - 86
Published on: Aug 16, 2025
Published by: Haemnet Ltd
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Keywords:
Related subjects:
© 2025 Marieke J A Verhagen, Sanna R Rijpma, Saskia E M Schols, published by Haemnet Ltd
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.